Yeast Transformation Lab Tutorial: A Step-by-Step Protocol

The yeast two-hybrid assay is a powerful biochemical technique developed in 1989 by Stanley Fields and Ok-Kyu Song at SUNY Stony Brook that enables researchers to study protein-protein interactions in vivo. The method exploits the modular nature of transcription factors like GAL4, where the DNA binding domain and activation domain can be separated and fused to different proteins. When two proteins of interest interact, they bring these domains together to reconstitute the transcription factor, activating reporter genes and indicating a protein-protein interaction. This technique has been widely adopted in research labs worldwide and has spawned various derivatives including yeast one-hybrid, three-hybrid systems, and reverse versions for screening interaction-deficient alleles, making it applicable for studying protein-DNA, protein-RNA, and protein-ligand interactions.

The Yeast Two-Hybrid (Y2H) system is a molecular biology technique that detects protein-protein interactions by fusing two proteins of interest to different domains of the GAL4 transcription factor; when the proteins interact, they bring together the DNA-binding and activation domains, enabling transcription of reporter genes (such as those encoding histidine biosynthesis enzymes) that allow yeast cells to grow on selective media lacking histidine, thereby indicating a successful protein interaction.

The yeast two-hybrid (Y2H) technique is a powerful molecular biology method that detects protein-protein interactions in vivo by exploiting the transcriptional activation properties of the Gal4 factor in Saccharomyces cerevisiae; it works by fusing two proteins of interest—one to the DNA-binding domain (bait) and another to the activation domain (prey)—so that when they interact, the activation domain approaches the regulatory regions of reporter genes, triggering transcription and allowing researchers to identify interacting protein pairs through phenotypic selection on selective media.

The yeast two-hybrid assay is a molecular biology technique that detects protein-protein interactions by utilizing a transcription factor with two separable domains: the DNA-binding domain (DBD) and the activation domain (AD). In this system, one protein of interest (the 'bait') is fused to the DBD, while another protein (the 'prey') is fused to the AD. When the bait and prey proteins interact, the DBD and AD come together to form a functional transcription factor that activates reporter gene expression; if no interaction occurs, transcription remains inactive. This allows researchers to identify and study protein-protein interactions in vitro.

The Yeast Two-Hybrid (Y2H) assay is a powerful molecular biology technique used to detect protein-protein interactions by splitting a transcription factor into two separate domains: a DNA-binding domain (BD) fused to one protein (bait) and an activation domain (AD) fused to another protein (prey). When the bait and prey proteins interact, the BD and AD domains are brought into proximity, reconstituting a functional transcription factor that activates a reporter gene (such as histidine synthase), allowing yeast cells to grow on selective media lacking histidine. This technique can be adapted into variants like Y1H (protein-DNA interactions), Y3H (protein-protein interactions mediated by RNA), and split ubiquitin Y2H (for membrane proteins).

Ambrx optimized engineered yeast for high productivity, achieving industrial-scale production in Italy. Artemisinic acid is converted to artemisinin through light-catalyzed processes mimicking plant chemistry, with tablets manufactured in Morocco. By May, 16 million treatments had been delivered to Africa, with capacity for 100-150 million annually—addressing half global needs. The same engineering principles apply to biofuels: microbes produce hydrocarbons (gasoline, diesel, jet fuel) that excrete directly, floating to broth surfaces for simple purification. Similar approaches can produce specialty chemicals (mouthwash, perfumes, carpet, paint) currently derived from petroleum, representing 15% of oil value but significant profit margins.

This webinar presents advances in engineering yeast for industrial biotechnology, covering two complementary approaches: (1) CRISPR-based genome editing combined with recombination-based DNA assembly enables rapid strain engineering, reducing development time from years to weeks; and (2) systems biology approaches using genome-scale metabolic models with proteome allocation constraints provide predictive frameworks for understanding and improving yeast metabolism. The speakers demonstrate how these technologies are transforming yeast from a platform for biofuels to a versatile host for pharmaceuticals, cosmetics, and nutrition products.

Native yeast metabolism for farnesene achieves only 23.8% theoretical yield from glucose. Amis engineered synthetic metabolic pathways achieving 28.6% glucose yield (20% improvement) and 170% oxygen utilization efficiency improvement. Implementation delivered 15% glucose yield improvement and over 70% oxygen consumption improvement. Remarkably, engineered strains exceeded theoretical limits of native metabolism, demonstrating that rational pathway redesign can surpass evolutionary constraints. CRISPR-Cas9 further accelerated gene editing from six weeks to one week per modification. This represents the future of industrial biotechnology: systematically redesigning metabolic networks to achieve performance impossible through natural evolution, enabling sustainable production of chemicals, fuels, and materials at commercial scales.

Researchers at QB3, UC Berkeley, have successfully transferred transporter genes from the fungus Neurospora crassa to Saccharomyces cerevisiae yeast, enabling the engineered yeast to simultaneously import and ferment both glucose and xylose—the two primary sugars in plant cell walls—thereby improving biofuel production efficiency through synthetic biology approaches.

Effective troubleshooting requires addressing issues one at a time. When one problem is resolved but other groups still show issues, multiple underlying problems exist. Using positive controls (known working plasmids) distinguishes between technique errors and scientific problems. If a positive control fails, the issue is with technique or reagents. If it works but experimental samples fail, the problem lies with experimental conditions or plasmid quality. Transformation efficiency measures colonies obtained per microgram of plasmid DNA. Low efficiency results from low plasmid concentration, poor cell competency, or suboptimal conditions. Competent cell quality can be assessed by comparing colony counts between different cell preparations.

When recombinant protein expression fails, systematically troubleshoot by first verifying if the protein is actually being expressed using Western blotting; if not expressed, check cloning accuracy and transformation efficiency; if expressed but absent from the supernatant, test for solubility issues by checking the pellet for inclusion bodies; if the protein is in the pellet, optimize conditions by lowering expression temperature, reducing inducer concentration, using fusion partners like SUMO or GST, or switching to different cell types; if the protein is soluble but purification fails, verify antibody specificity and optimize purification parameters.

When optimizing recombinant protein expression in bacterial cells, first determine whether the issue is lack of expression or improper folding by comparing pre- and post-induction SDS-PAGE samples; if the protein is expressed but insoluble, try lowering the temperature (e.g., 16°C), reducing induction strength (e.g., lower IPTG concentration), using different cell strains (like Rosetta for rare codons), or adding fusion partners (SUMO, GST, MBP) to aid solubility and folding; if these simple optimizations fail, consider switching to more complex expression systems like yeast, insect cells, or mammalian cells (CHO, 293) for proteins requiring post-translational modifications or proper folding assistance.

Common challenges in recombinant protein production include: (1) No or low expression: Caused by incorrect reading frame (addressed by bidirectional sequencing), protein toxicity (addressed by low-copy plasmids and tunable promoters), or codon bias (addressed by codon-optimized strains like BL21(DE3) RIL); (2) Inclusion body formation: Occurs when proteins cannot fold properly, addressed by directing proteins to periplasm, inducing at lower rates, or using chaperone-expressing strains; (3) Protein inactivity: Often due to lack of proper PTMs or improper folding, addressed by changing expression systems or inducing at lower temperatures.

One common problem in protein expression is complete lack of protein production, which can occur if the protein is toxic to the host bacteria. Toxic proteins can kill bacteria before induction, preventing expression. The problem may also result from leaky expression (protein production before induction), which can be fatal for toxic proteins. For lac-based promoters, adding glucose (0.2-2%) to the growth medium inhibits expression by repressing the lac promoter. For T7-based systems, using BL21(DE3) pLysS bacteria, which express T7 lysozyme, can reduce leaky expression. When proteins are toxic to host bacteria, several strategies can improve expression. Using C41 or C43 bacterial strains, which have additional membrane proteins, can help bacteria survive toxic protein expression. Adding signal peptides can direct proteins to the periplasm, reducing toxicity. Using lower copy number plasmids reduces protein concentration. Codon optimization involves changing rare codons in a gene sequence to improve expression in the host organism. Rare codons can slow translation and reduce protein yield. The software can optimize codons for specific host organisms. However, codon optimization must be balanced with the need to maintain protein structure, as some rare codons may be important for proper protein folding. Different host strains have different codon pools, and choosing the appropriate host can improve expression without codon optimization. For protein expression in Erlenmeyer flasks, the culture volume should not exceed 50% of the flask capacity (50 ml in a 250 ml flask). Excessive volume reduces aeration, which is critical for bacterial growth and protein expression. The flask should be shaken to provide adequate oxygenation. Excessive agitation can cause foam formation, which may require antifoaming agents. Disulfide bonds form between cysteine residues and are important for proper protein folding. In the reducing environment of the bacterial cytoplasm, disulfide bonds cannot form correctly. To express proteins with disulfide bonds, researchers should use periplasmic expression (with signal peptides) or specialized strains like Origami, which have a more oxidizing cytoplasm. Proper disulfide bond formation is essential for protein stability and function. Chaperone-assisted protein folding can be achieved by co-transforming with chaperone plasmids or adding benzyl alcohol to the growth medium. Lower expression temperatures (15-25°C) can improve folding by reducing aggregation. Chromatography separates proteins based on their interactions with a stationary phase and a mobile phase. Affinity chromatography using His-tag exploits the nickel-binding property of histidine residues. The protein binds to nickel ions in the stationary phase. The column is washed to remove unbound proteins. The target protein is eluted using imidazole, which competes for nickel binding. Size exclusion chromatography separates proteins based on size. The column contains porous beads that proteins cannot enter. Large proteins pass through the column faster (elute first), while small proteins enter the pores and elute later. Ion exchange chromatography separates proteins based on charge. The stationary phase contains charged groups that bind proteins of opposite charge. A salt gradient (like NaCl) is used to elute proteins by competing for binding sites. Hydrophobic interaction chromatography separates proteins based on hydrophobicity. The stationary phase is hydrophobic, and proteins bind through hydrophobic interactions. A gradient of organic solvent (like acetonitrile) is used to elute proteins by reducing hydrophobic interactions. After purification, protein activity must be verified. For enzymes, zymography (zymogram) can be used, where the gel contains substrate. Active enzymes will degrade the substrate, creating clear zones on the gel. This assay confirms both protein presence and activity. Inactive proteins may indicate improper folding or degradation. Zymography is particularly useful for verifying enzyme function after purification. Western blotting detects specific proteins in a sample. Proteins are separated by SDS-PAGE, then transferred to a membrane (nitrocellulose or PVDF). The membrane is blocked with BSA or milk to prevent non-specific binding. Primary antibodies specific to the target protein are applied, followed by secondary antibodies conjugated to enzymes. The enzyme-substrate reaction produces a visible signal. Western blotting requires antibodies specific to the target protein. These can be purchased commercially or produced in animals. To produce antibodies, the target protein is injected into an animal (like a rabbit), and the animal's immune system produces antibodies against it. The antibodies are then purified from the animal's blood.